144 related articles for article (PubMed ID: 38228954)
1. Exagamglogene Autotemcel: First Approval.
Hoy SM
Mol Diagn Ther; 2024 Mar; 28(2):133-139. PubMed ID: 38228954
[TBL] [Abstract][Full Text] [Related]
2. Exagamglogene Autotemcel for Transfusion-Dependent β-Thalassemia.
Locatelli F; Lang P; Wall D; Meisel R; Corbacioglu S; Li AM; de la Fuente J; Shah AJ; Carpenter B; Kwiatkowski JL; Mapara M; Liem RI; Cappellini MD; Algeri M; Kattamis A; Sheth S; Grupp S; Handgretinger R; Kohli P; Shi D; Ross L; Bobruff Y; Simard C; Zhang L; Morrow PK; Hobbs WE; Frangoul H;
N Engl J Med; 2024 May; 390(18):1663-1676. PubMed ID: 38657265
[TBL] [Abstract][Full Text] [Related]
3. Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-Thalassemia.
Parums DV
Med Sci Monit; 2024 Mar; 30():e944204. PubMed ID: 38425279
[TBL] [Abstract][Full Text] [Related]
4. Exagamglogene Autotemcel for Severe Sickle Cell Disease.
Frangoul H; Locatelli F; Sharma A; Bhatia M; Mapara M; Molinari L; Wall D; Liem RI; Telfer P; Shah AJ; Cavazzana M; Corbacioglu S; Rondelli D; Meisel R; Dedeken L; Lobitz S; de Montalembert M; Steinberg MH; Walters MC; Eckrich MJ; Imren S; Bower L; Simard C; Zhou W; Xuan F; Morrow PK; Hobbs WE; Grupp SA;
N Engl J Med; 2024 May; 390(18):1649-1662. PubMed ID: 38661449
[TBL] [Abstract][Full Text] [Related]
5. CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia.
Frangoul H; Altshuler D; Cappellini MD; Chen YS; Domm J; Eustace BK; Foell J; de la Fuente J; Grupp S; Handgretinger R; Ho TW; Kattamis A; Kernytsky A; Lekstrom-Himes J; Li AM; Locatelli F; Mapara MY; de Montalembert M; Rondelli D; Sharma A; Sheth S; Soni S; Steinberg MH; Wall D; Yen A; Corbacioglu S
N Engl J Med; 2021 Jan; 384(3):252-260. PubMed ID: 33283989
[TBL] [Abstract][Full Text] [Related]
6. Elivaldogene Autotemcel: First Approval.
Keam SJ
Mol Diagn Ther; 2021 Nov; 25(6):803-809. PubMed ID: 34424497
[TBL] [Abstract][Full Text] [Related]
7. Gene editing for sickle cell disease and transfusion dependent thalassemias- A cure within reach.
Eckrich MJ; Frangoul H
Semin Hematol; 2023 Jan; 60(1):3-9. PubMed ID: 37080708
[TBL] [Abstract][Full Text] [Related]
8. Hematopoietic Stem Cell Transplantation in Sickle Cell Disease: A Multidimentional Review.
Rostami T; Rad S; Rostami MR; Mirhosseini SA; Alemi H; Khavandgar N; Janbabai G; Kiumarsi A; Kasaeian A; Mousavi SA
Cell Transplant; 2024; 33():9636897241246351. PubMed ID: 38680015
[TBL] [Abstract][Full Text] [Related]
9. Genome editing using CRISPR-Cas9 to create the HPFH genotype in HSPCs: An approach for treating sickle cell disease and β-thalassemia.
Ye L; Wang J; Tan Y; Beyer AI; Xie F; Muench MO; Kan YW
Proc Natl Acad Sci U S A; 2016 Sep; 113(38):10661-5. PubMed ID: 27601644
[TBL] [Abstract][Full Text] [Related]
10. In brief: Casgevy for beta thalassemia.
Med Lett Drugs Ther; 2024 May; 66(1702):79. PubMed ID: 38696313
[No Abstract] [Full Text] [Related]
11. The Novel Role of the B-Cell Lymphoma/Leukemia 11A (BCL11A) Gene in β-Thalassaemia Treatment.
Mahmoud Ahmed NH; Lai MI
Cardiovasc Hematol Disord Drug Targets; 2023; 22(4):226-236. PubMed ID: 36734897
[TBL] [Abstract][Full Text] [Related]
12. Development of pathophysiologically relevant models of sickle cell disease and β-thalassemia for therapeutic studies.
Gupta P; Goswami SG; Kumari G; Saravanakumar V; Bhargava N; Rai AB; Singh P; Bhoyar RC; Arvinden VR; Gunda P; Jain S; Narayana VK; Deolankar SC; Prasad TSK; Natarajan VT; Scaria V; Singh S; Ramalingam S
Nat Commun; 2024 Feb; 15(1):1794. PubMed ID: 38413594
[TBL] [Abstract][Full Text] [Related]
13. Specificity of CRISPR-Cas9 Editing in Exagamglogene Autotemcel.
Yen A; Zappala Z; Fine RS; Majarian TD; Sripakdeevong P; Altshuler D
N Engl J Med; 2024 May; 390(18):1723-1725. PubMed ID: 38657268
[No Abstract] [Full Text] [Related]
14. Systemic medications for sickle cell disease and potential applications for sickle cell retinopathy.
Garg AK; Scott AW
Curr Opin Ophthalmol; 2024 May; 35(3):185-191. PubMed ID: 38465910
[TBL] [Abstract][Full Text] [Related]
15. Betibeglogene Autotemcel Gene Therapy for Non-β
Locatelli F; Thompson AA; Kwiatkowski JL; Porter JB; Thrasher AJ; Hongeng S; Sauer MG; Thuret I; Lal A; Algeri M; Schneiderman J; Olson TS; Carpenter B; Amrolia PJ; Anurathapan U; Schambach A; Chabannon C; Schmidt M; Labik I; Elliot H; Guo R; Asmal M; Colvin RA; Walters MC
N Engl J Med; 2022 Feb; 386(5):415-427. PubMed ID: 34891223
[TBL] [Abstract][Full Text] [Related]
16. Base editing of haematopoietic stem cells rescues sickle cell disease in mice.
Newby GA; Yen JS; Woodard KJ; Mayuranathan T; Lazzarotto CR; Li Y; Sheppard-Tillman H; Porter SN; Yao Y; Mayberry K; Everette KA; Jang Y; Podracky CJ; Thaman E; Lechauve C; Sharma A; Henderson JM; Richter MF; Zhao KT; Miller SM; Wang T; Koblan LW; McCaffrey AP; Tisdale JF; Kalfa TA; Pruett-Miller SM; Tsai SQ; Weiss MJ; Liu DR
Nature; 2021 Jul; 595(7866):295-302. PubMed ID: 34079130
[TBL] [Abstract][Full Text] [Related]
17. Preclinical evaluation for engraftment of CD34
Uchida N; Li L; Nassehi T; Drysdale CM; Yapundich M; Gamer J; Haro-Mora JJ; Demirci S; Leonard A; Bonifacino AC; Krouse AE; Linde NS; Allen C; Peshwa MV; De Ravin SS; Donahue RE; Malech HL; Tisdale JF
Cell Rep Med; 2021 Apr; 2(4):100247. PubMed ID: 33948577
[TBL] [Abstract][Full Text] [Related]
18. Precision Editing as a Therapeutic Approach for β-Hemoglobinopathies.
Paschoudi K; Yannaki E; Psatha N
Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298481
[TBL] [Abstract][Full Text] [Related]
19. Casgevy and Lyfgenia: Two gene therapies for sickle cell disease.
Med Lett Drugs Ther; 2024 Jan; 66(1694):9-10. PubMed ID: 38212256
[No Abstract] [Full Text] [Related]
20. Therapeutic perspective for children and young adults living with thalassemia and sickle cell disease.
Ferraresi M; Panzieri DL; Leoni S; Cappellini MD; Kattamis A; Motta I
Eur J Pediatr; 2023 Jun; 182(6):2509-2519. PubMed ID: 36997768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
